ASCO Sarcoma

Anlotinib Offers Efficacy Across Subtypes of Soft-Tissue Sarcoma
June 13, 2016

A phase II trial showed that the tyrosine kinase inhibitor anlotinib has promising efficacy across a variety of subtypes of advanced refractory soft-tissue sarcoma.

Gemcitabine Plus Pazopanib Shows Promise in Soft-Tissue Sarcomas
June 07, 2016

Combined therapy with gemcitabine and pazopanib appears to be a viable treatment option for patients with soft-tissue sarcomas refractory to anthracycline or ifosfamide.

Quality of Life Could Help Select Treatment for Soft-Tissue Sarcoma
June 07, 2016

Understanding quality of life and the detrimental impact of disease progression is critical for long-term care and survival of patients with soft-tissue sarcoma.